Diagnosis & Disease Information

Novel Peptide-Based ESA Promising

BARCELONA—A novel peptide-based erythropoiesis-stimulating agent (ESA) called Hematide safely raises hemoglobin levels in anemic CKD patients and maintains stable hemoglobin levels in hemodialysis patients who switch to the drug from epoetin alfa, data suggest.

Once Monthly C.E.R.A. Found Beneficial

BARCELONA—Once-monthly dosing of continuous erythropoietin receptor activator (C.E.R.A.) maintains stable hemoglobin levels in CKD patients regardless of age, gender, or comorbidities, according to study data presented here at the 44th Congress of the European Renal Association-European Dialysis and Transplant Association.

Untreated Anemia Increases Morbidity

CHICAGO—Diabetics with CKD whose anemia is untreated have twice the overall risk of CVD-related hospitalizations, according to data reported at the 67th Scientific Sessions of the American Diabetes Association.

Next post in News